| Name | Title | Contact Details |
|---|
GHX is a software-as-a-service company that`s reducing the cost of doing business in healthcare by automating supply chain processes and improving visibility into the products used in patient care. We`ve built the GHX Global Network, the world`s largest community of healthcare trading partners, connecting supply chain, finance and clinical professionals with their suppliers. Our cloud-based technology makes it easier for customers to drive costs out of the healthcare supply chain. Since 2010, we`ve saved the healthcare industry $5+ billion. Today we`re expanding our solutions to further enhance data management and allow integration of clinical and business systems. The Industry We Serve Our focus is on the healthcare supply chain, through which hospitals and their suppliers buy and deliver the thousands of medical-surgical supplies that clinicians need to effectively care for patients. For most hospitals, supply chain costs are the second largest and fastest growing operational expense, so reining in these costs is imperative. Our Products and Services At the heart of GHX is the GHX Exchange, a platform that connects healthcare providers and suppliers so they can work together electronically. This helps lower costs and simplifies supply chain management by eliminating error-prone, manual order processes. GHX solutions include: • An open and neutral electronic trading exchange • Procurement and accounts payable automation • Content, contract and inventory management • Business intelligence and reporting • Standards enablement and data synchronization
Talika Beauty is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.
Scimega Research Inc is a Laval, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
FocusOne is a Omaha, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.